James Ratcliff joined Game Rant in 2022 as a Gaming News Writer. In 2023, James was offered a chance to become an occasional feature writer for different games and then a Senior Author in 2025. He is ...

Philanthropist and billionaire MacKenzie Scott announced Tuesday she has given $7.1 billion in donations to nonprofits so far in 2025, a major increase over her recent yearly contributions. Writing in ...

Eric Law is a Game Rant contributor from Pennsylvania, USA. An MMORPG-focused video game writer for Game Rant for two years and counting, Eric cut his teeth on gaming since he was a wee lad watching ...

Spring Framework 7.0 retains a JDK 17 baseline while at the same time recommending JDK 25 as the latest LTS release. It also introduces a Jakarta EE 11 baseline and embraces Kotlin 2.2 as well as ...

The 7.38 Patch for Final Fantasy 14 has arrived, bringing with it a number of battle system updates, new items, resolved issues, and more! This page acts as a comprehensive breakdown of the 7.38 Patch ...

Apple has just released iOS 18.7.2, a full two days after iOS 26.1 landed. Is this the last call for iOS 26 resisters? Here’s what’s in it and how to get it. Alongside iOS 18.7.2, Apple also released ...

Apple recently released the iOS 26.1 and iOS 18.7.2 software updates to the public. Both of the updates have already been put through their paces to figure out how they impact the iPhone’s battery ...

Apple released a new update to its iPhone software on Monday, Sept. 30: iOS 26.0.1. But what if your phone can’t run iOS 26.0.1 or, since the next-gen software is just two weeks old, you’re reluctant ...

Apple today released iOS 26.0.1 and iPadOS 26.0.1, the first updates to the iOS 26 and iPadOS 26 operating systems that came out earlier this week. The new software can be downloaded on eligible ...

Apple today seeded a second release candidate version of macOS Sequoia 15.7, one week after seeding the first release candidate. If no further bugs are found, macOS Sequoia 15.7 could be released to ...

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and ...